IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation

Bone Marrow Transplantation

Volumn 23, Issue 2, 1999, Pages 183-185

  Nagayama, H ^a   Takahashi, S ^a   Takahashi, T ^a   Ogami, K ^a   Ikebuchi, K ^a   Tojo, A ^a   Tani, K ^a   Asano, S ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

GVHD; LAK cells; Refractory acute monoblastic leukemia; rIL 2; uBMT

Indexed keywords

INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ACUTE MONOCYTIC LEUKEMIA; ADOPTIVE TRANSFER; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLAST CELL; CASE REPORT; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE TRANSFUSION; LYMPHOKINE ACTIVATED KILLER CELL; PRIORITY JOURNAL; RELAPSE; TREATMENT FAILURE;

EID: 0032935129     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701550     Document Type: Article

References (10)

1. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729-1734.
2. Meloni G, Foa R, Vignetti M et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994; 84: 2158-2163.
3. Mehta J, Powles R, Singhal S et al. Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16: 133-137.
4. Robinson N, Benyunes MC, Thompson JA et al. Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study. Bone Marrow Transplant 1997; 19: 435-442.
5. Robinson N, Sanders JE, Benyunes MC et al. Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood 1996; 87: 1249-1254.
6. Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994; 84: 964-971.
7. Bosco MC, Espinoza-Delgado I, Schwabe M et al. The γ subunit of the interleukin-2 receptor is expressed in human monocytes and modulated by interleukin-2, interferon γ, and transforming growth factor β 1. Blood 1994; 83: 3462-3467.
8. Barnett D, Granger V, Reilly JT. Expression of the p75 interleukin-2 receptor (β subunit) in acute and chronic leukaemia. Br J Haematol 1990; 76: 314-315.
9. O'Brien D, Boughton B. High and low affinity IL-2 receptors on human leukaemic blast cells. Br J Haematol 1990; 76: 315-317.
10. Foa R, Meloni G, Tosti S et al. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. Br J Haematol 1991; 77: 491-496.